Comparative Pharmacology
Head-to-head clinical analysis: CAPEX versus DESOXIMETASONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CAPEX versus DESOXIMETASONE.
CAPEX vs DESOXIMETASONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties.
Desoximetasone is a potent corticosteroid that binds to glucocorticoid receptors, modulating gene expression and inhibiting phospholipase A2, thereby reducing prostaglandin and leukotriene synthesis. This leads to anti-inflammatory, antipruritic, and vasoconstrictive effects.
Topical application of a thin film twice daily to affected areas. Not for ophthalmic, oral, or intravaginal use.
Apply a thin film to affected skin areas twice daily.
None Documented
None Documented
Terminal elimination half-life is approximately 1.5–2 hours. This short half-life supports twice-daily dosing for maintenance of therapeutic levels.
Clinical Note
moderateDesoximetasone + Gatifloxacin
"The risk or severity of adverse effects can be increased when Desoximetasone is combined with Gatifloxacin."
Clinical Note
moderateDesoximetasone + Rosoxacin
"The risk or severity of adverse effects can be increased when Desoximetasone is combined with Rosoxacin."
Clinical Note
moderateDesoximetasone + Levofloxacin
"The risk or severity of adverse effects can be increased when Desoximetasone is combined with Levofloxacin."
Clinical Note
moderateTerminal elimination half-life is approximately 1.5–2 hours. Due to its topical use, systemic half-life is less clinically relevant; however, prolonged use on large areas or under occlusion may lead to systemic accumulation.
Primarily renal (hepatic metabolism to inactive metabolites; <1% excreted unchanged in urine). Fecal elimination accounts for <5%.
Primarily renal (urinary) as inactive metabolites, with less than 5% unchanged drug. Fecal excretion accounts for a minor fraction, primarily via bile.
Category C
Category A/B
Topical Corticosteroid
Topical Corticosteroid
Desoximetasone + Trovafloxacin
"The risk or severity of adverse effects can be increased when Desoximetasone is combined with Trovafloxacin."